Our obligations

Under the National Blood Agreement, we're required to:

  • monitor the national and international environment in which the Australian Blood Sector operates for new technological, clinical, risk or other developments that may impact on the national blood supply
  • maintain a systematic approach to identifying new developments, and providing a clearinghouse and coordination function for information in relation to new development.

Our framework

We monitor international developments that may influence blood and blood product management in Australia.

Our focus is on:

  • information that may have an impact on global supply, demand and pricing, such as changes in company structure, capacity, organisation and ownership
  • potential new product developments and applications
  • global regulatory and blood practice trends
  • other emerging risks that could potentially put financial or other pressures on the Australian sector.

Current areas of interest:

  • Fresh blood: transmissible disease, manufacturing, testing, synthetic blood products, adverse reactions and haemovigilance
  • Plasma products: transmissible disease, manufacturing, new uses and products, international pricing (demand) and international pricing (supply)
  • Blood management: techniques (before, during and after surgery), risk identification, overseas programs and demand management during constrained supply
  • Recombinant products: new uses and products, changes to products, supply, demand and price and adverse reactions
  • Policy and regulation: Australia and overseas
  • Logistics.

Last updated: 27 Mar 2024